• Featured Story

    Medicine Pills Stacked Like Increasing Graph on Newly Designed U.S. One Hundred Dollar Bills.

    No one is thrilled with the way new drugs and medical devices come to market in the U.S. - not the biotech and pharmaceutical companies, not the regulators at the Food and Drug Administration (FDA) or National Institutes of Health (NIH), not physicians, and certainly not patients desperately in need of new therapies.

    The process is hugely expensive and incredibly slow. According to the Tuft's Center for the Study of Drug Development, the average cost of bringing a new prescription drug from lab to market now tops $2.5 billion and takes more than 10 years.

    That can make for a real thrill ride where investors are concerned, as share price for a pre-profit biotech can rise and fall dramatically and unpredictably with every related data release, financial report, news item, or regulatory hiccup over an entire decade, making long-term investment a crapshoot, at best.

    But new regulations on the table could change everything for biotech investors and critically ill patients...

biotech stocks

How You Made 53% in Two Months with This Biotech Stock

Biotech Stock

We first recommended this incredible biotech stock in 2013. It's since realized a growth of 342%.

And better yet: it's expected to continue growing at an exponential rate.

Here's why you should add stellar security to your portfolio...

This Top Biotech Stock Just Got a $100 Billion "Buy" Signal

Global cancer spending topped $100 billion for the first time after climbing a whopping 10% in 2014.

And that's a major "buy" signal for one of the top biotech stock picks we've been recommending at Money Morning.

According to a report from the IMS Institute of Health, rising drug prices and increased incidence of cancer led to the 10% spike in drug spending last year.

Here's what that means for our top investment...

Biotech Investing for Beginners: Your 7-Step Guide

Biotech news

Biotech investing can be tricky. The industry is complicated, and the stocks are volatile.

But the profit payoff can be life-changing.

That's why we've created the "Biotech Investing for Beginners Guide" with Money Morning's Biotech Investing Specialist Ernie Tremblay.

That's because many of the metrics we use to evaluate other stocks - like P/E ratio, profit margin, earnings per share - don't always apply to biotech stocks.

Here's Tremblay's step-by-step guide to investing in biotech stocks...

Two Divergent Northbound Stocks to Buy Right Now

biotech

I want to spend today talking to you about two stocks that we've repeatedly recommended to Private Briefing readers.

Both stocks made bullish headlines last week.

One of the stocks is a winner - a big winner, in fact. And the other has been a loser - so far.

But we're predicting it will be a big winner, too - a huge winner.

And last week's developments strengthened our case...

2015 Top Stock Picks: AMBA, SWKS, RMBS

market volatility

Our Money Morning 2015 top stock picks have seen biotech hit a snag.

But in that time, semiconductor tech stocks have been up big - as much as 45% for one name.

Here's how the big chipmaker tech stocks are doing, as well as some of our other 2015 top stock picks...

The 3 Best Biotech Stocks to Buy at Today's Discounted Prices

Best biotech stocks

The biotech market has sold off last week, with the Nasdaq Biotechnology Index dropping 6.4% since April 23. And because of that, some of the best biotech stocks have dipped as well.

Now, investors are wondering if they should take their money to the sideline. But Money Morning's Bioscience Investing specialist Ernie Tremblay says this type of move is normal for the biotech market.

Here are three stocks we're recommending now that they're trading at discounted prices...

2015 Top Stock Picks: PRTA, AMBA, RMBS

If you’ve been following our Money Morning 2015 top stock picks, you may notice a big shakeup from last week.

That’s right, some of the best biotech stock to buy right now are only up somewhere between 30% and 50%.

Here’s why this sell-off isn’t going to rain on biotech’s parade…

Why Biotech Stocks Are Down This Week

biotech stocks

Investors are again worried about a biotech bubble as biotech stocks take another big hit this week.

Since April 23, the Nasdaq Biotechnology Index has dropped 6.8%. During the same time, the S&P Biotechnology Industry Index is down 8.5%.

But this is not a biotech bubble we're seeing...

2015 Top Stock Picks: NVAX, SWKS, AMBA

top stock picks

The Money Morning 2015 top stock picks show that biotech is still red-hot. But elsewhere in tech, particularly in semiconductors, we see another exciting market development for 2015.

Our 2015 top stock picks list still has the same two biotech names, Prothena Corp. Plc (Nasdaq: PRTA) and Lannett Company Inc. (NYSE: LCI), leading the pack. But Novavax Inc. (Nasdaq: NVAX), a biotech that corrected late March, is back in the No. 3 spot. Then there are semiconductors, which are also seeing a good year.

Here's our full list of our top performing stock picks so far in 2015...

This 632% Biotech Winner Is About to Go Even Higher

best stocks to buy

There are great companies, and there are companies that do great things in the marketplace... and for your health.

The latter is the kind of company I'm talking about here.

And it's the reason why its stock has soared and will continue to soar as the years roll on...

2015 Top Stock Picks: SLCA, PRTA, LCI

tech stocks in 2015

Our 2015 top stock picks include a number of biotech stocks, a "frac sand" company, and one company that may be overheating.

Topping the list of our 2015 top stock picks include red-hot biotech names. Crude oil prices are still weak - a function of increased U.S. domestic energy production - but that hasn't soured gains for this frac sand company.

But be warned, not all of these top stocks are a buy...

Why Gilead (Nasdaq: GILD) Is Still A Biotech Stock to Buy

Nasdaq: GILD

Gilead Sciences Inc. (Nasdaq: GILD) is facing criticism again this week for its highly priced Hepatitis C drug Sovaldi. The drug costs $1,000 per pill.

According to The Wall Street Journal, many states have restricted access to the drug, leaving some patients unable to afford the treatment.

But despite the criticism, Gilead (Nasdaq: GILD) stock remains one of the best biotech stocks to buy today. Here's why...

The Best Cheap Stocks to Invest in Now with Breakout Potential

cheap stocks to invest in

The biotech industry is offering some of the best cheap stocks to invest in now.

You see, biotech stocks have faltered in the last two weeks. Since March 20, the Nasdaq Biotechnology Index has dipped nearly 7%.

But this isn't a time to sell. We're adding to our biotech stock positions now. Here are the best cheap stocks to invest in today...

How to Profit from America's $20 Billion Waistline War

Top pharmaceutical companies

Weight loss is a $20 billion per year industry. Yet, it seems the more we spend on shedding pounds, the more pounds we have to shed. Today, two-thirds of adults and one-third of children in the U.S. are overweight or obese, and the numbers are climbing.

With a growing market of that magnitude and so much money changing hands, it's no wonder investors' eyes light up when they hear the words "new obesity drug."

But if you want to find the "gold in those hills," that is, to invest in a stock that will really pay off, you have to know where to look.

Because if you stake a claim in the wrong place, you may lose more weight from your wallet than your waistline...

Sell-Off in Biotech Stocks Making for Attractive Entry Points

U.S. stock futures

Last week on our roundup of the 2015 top stocks to invest in, we highlighted biotech stocks for their explosive growth in 2015 and their continued potential.

And while biotech stocks got creamed this past week. They're still among the best investments for 2015.

Just look at our top stocks to invest in for 2015, which still features a few biotech stocks as our best performers...

© 2015 Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201, Email: customerservice@MoneyMorning.com